Telehealth Clinic Revenue Model: Subscription vs Pay-Per-Visit

Match the model to the medication. Chronic, maintenance categories — TRT, HRT, hair loss, skin — fit a subscription model, where bundled refills produce predictable recurring revenue and higher lifetime value. Episodic or acute needs fit pay-per-visit, which lowers the barrier to a first purchase but retains poorly. Most durable clinics run a hybrid: a low visit fee to enter, subscription refills to compound.

The choice between subscription and pay-per-visit is the single decision that shapes a telehealth clinic's growth, cash flow, and valuation more than any other. It is also the one operators most often make backwards — picking the model that sounds like a real business (recurring revenue) or the one that feels honest (charge per visit) instead of the one the medications actually justify. The right answer falls out of the category you dispense, the math of acquisition, and how you want cash to arrive. This is the plain-spoken version of that decision.

---

Should a Telehealth Clinic Use Subscription or Pay-Per-Visit?

Start from the medication, not the pricing page. If patients take a drug continuously — testosterone, hormones, finasteride, tretinoin — a subscription matches the clinical reality and turns each patient into recurring revenue. If the need is one-and-done — an acute infection, a single episodic script — there is nothing to subscribe to, and pay-per-visit is the honest fit. The model should follow the treatment.

This is why the category question comes first. A hair-loss clinic and an acute-care clinic are not choosing between the same two options with different preferences; they are dispensing different kinds of medicine that produce different revenue shapes. Forcing a subscription onto an episodic category creates churn and refund pressure. Forcing pay-per-visit onto a maintenance category leaves recurring revenue — and lifetime value — on the table. The unit economics behind each model only make sense once the category is settled.

---

How Does Subscription Compare to Pay-Per-Visit?

Subscription bills a patient on a recurring schedule, usually bundling the medication refill and any ongoing provider oversight into one predictable charge. Pay-per-visit charges per encounter or per order, with no ongoing commitment. The first produces MRR, higher lifetime value, and cash-flow visibility; the second produces lower commitment, easier first purchases, and worse retention. Here is the head-to-head.

Model	How revenue accrues	Best-fit category	Retention / LTV	Cash flow	Primary risk
Subscription / membership	Recurring monthly or quarterly charge; refills bundled	Chronic maintenance (TRT, HRT, hair loss, skin, weight management)	High — LTV compounds with every retained cycle	Predictable MRR; easier to forecast and finance	Churn and auto-renewal compliance; refunds if value lapses
Pay-per-visit / one-time	Per-encounter or per-order fee, no commitment	Episodic / acute (single scripts, one-off consults)	Low — each purchase must be re-earned	Lumpy and campaign-dependent	Constant re-acquisition; CAC re-incurred per sale
Hybrid (visit fee + subscription refills)	One-time visit fee to enter, recurring refill billing	Maintenance meds needing an initial clinical review	High, with a lower entry barrier	Front-loaded first order, recurring thereafter	Complexity; two billing events to disclose cleanly

The pattern in the market is clear. The large direct-to-consumer players — Hims & Hers, Ro — built their scale on recurring subscriptions for maintenance categories, using a low or free first touch to acquire and recurring refills to retain and monetize. You can see the shape in Hims & Hers' investor materials, where subscriber counts and recurring revenue, not one-time visits, are the reported drivers. That is not an accident of branding; it is the category doing the work.

---

How Does the Model Interact With LTV:CAC?

The model you choose largely determines whether you can hit the benchmark investors expect. The commonly cited healthy ratio is roughly 3:1 lifetime value to customer acquisition cost. Acquisition cost is paid once; a subscription spreads dozens of refill orders across that single cost, so lifetime value climbs the longer a patient stays. Pay-per-visit has to re-earn — and often re-pay for — each patient.

Work the intuition. Suppose acquiring a patient costs the same in both models. Under pay-per-visit, one purchase might barely clear that cost, and the second purchase requires winning the patient back, sometimes at full acquisition price again. Under subscription, the same acquired patient produces a refill every cycle, and lifetime value is the margin per refill multiplied by how many cycles they stay. This is exactly why maintenance categories gravitate to subscription: the medicine is recurring, so the revenue should be too. We hold the specific targets in the CAC and LTV benchmarks to hold yourself to, and acquisition cost itself swings hard by category — see how acquisition cost varies by medication category.

The honest caveat: subscription only improves LTV:CAC if patients stay. A subscription with high early churn can be worse than clean transactional revenue, because you have booked expectations of recurring value that never materialize and invited refund and chargeback pressure. Retention is the load-bearing assumption, and its mechanics — onboarding, refill adherence, cancellation recovery — are their own discipline. A sibling piece covers those tactics in depth; this post stays on the model-choice question.

---

How Does the Model Affect Gross Margin and Cash Flow?

Billing model does not set gross margin directly — category and fulfillment cost do — but it changes how margin behaves over a patient's life. The first order carries the heavy costs: acquisition, the initial clinical review, onboarding. Later refills carry mostly medication and fulfillment cost. So a subscribed patient's blended margin improves the longer they stay, while pay-per-visit re-incurs the heavy first-order costs on every purchase.

Cash flow diverges just as sharply. Subscription revenue is predictable: you can forecast next quarter's MRR from your current base and churn rate, which makes the business easier to plan, staff, and finance. Pay-per-visit revenue is lumpy and campaign-dependent — a good ad month is a good revenue month, and a quiet one is not. For an operator trying to plan pharmacy volume, provider capacity, and working capital, predictable beats large-but-erratic. The margin mechanics across order types are worked through in how gross margin behaves across order types, and the way refills specifically compound is in how subscription refill revenue actually compounds.

---

When Is a Hybrid the Right Answer?

Most often. A hybrid charges a modest one-time visit or consultation fee to start — covering the clinical review and lowering the barrier to a first purchase — then bills a recurring subscription for the ongoing refills. It captures the strength of both: transactional entry, recurring monetization. For any maintenance medication that needs an initial provider evaluation, this is usually the strongest shape.

The hybrid resolves the central tension. A pure subscription asks a stranger to commit to recurring billing before they trust you, which suppresses conversion. A pure pay-per-visit leaves the recurring value of a maintenance drug uncaptured. The hybrid lets the visit do acquisition and the refill do the business. Practical guidelines:

• Use a low or zero entry fee where acquisition is competitive and the recurring value is high (hair loss, skin, TRT).
• Charge a real visit fee where the clinical review is substantial and you want to filter for intent.
• Keep the subscription tied to an actual continuing medication — do not manufacture recurrence a patient does not clinically need.
• Make the two billing events legible: patients should understand exactly what the visit fee buys and what the subscription bills.

---

What Compliance Rules Apply to Subscription Billing?

Recurring billing is regulated as a negative option. Under the FTC's negative-option and auto-renewal rules, any offer that bills a customer on a recurring basis unless they cancel must clearly and conspicuously disclose the material terms, obtain the customer's express informed consent before charging, and provide a simple mechanism to cancel. This is enforced, and getting it wrong turns a subscription into a liability.

Two obligations sit on top for telehealth specifically. First, a subscription bills automatically, but it cannot auto-approve medicine — every refill still requires a valid prescription and, where the category or state demands it, a provider's review before it ships. Automatic billing and automatic dispensing are not the same thing, and conflating them is a clinical and legal error. Second, the disclosure and cancellation standards from the FTC's advertising and marketing guidance apply to how you present the offer. Build clear terms, express consent, easy cancellation, and a real clinical review into the subscription flow from the first version, not as a later patch.

---

Why the System of Record Decides Who Actually Wins

Whichever model you choose, the durable advantage is not the billing shape — it is who owns the patient record and the refill data. Lifetime value only compounds if you can see the patient across every cycle: what they take, when they are due, why they churned, when to reach them. An operator who owns that record can run any model well; one whose data is scattered across a storefront, a pharmacy portal, and a spreadsheet cannot.

This is the part the revenue-model debate usually misses. Subscription is a bet that you can retain a patient over many cycles, and you can only make that bet pay if the refill loop is operationally reliable — the right patient, the right medication, the right provider approval, on schedule, every time. That reliability is an infrastructure problem, not a pricing one. neolife is the fulfillment rail that sits on top of the compounding pharmacy a clinic already uses: AI-native intake, compliance, and cross-pharmacy order routing, with a licensed provider approving every order. Operators keep their own storefront, own their patient data as the system of record, and add pharmacies without a rip-and-replace. That is what makes recurring refills dependable enough to build a subscription business on — and what lets the patient record, not the pharmacy, be the thing that compounds.

---

Key Takeaways

• The medication category decides the model: maintenance meds (TRT, HRT, hair loss, skin) fit subscription; episodic or acute needs fit pay-per-visit.
• Subscription delivers predictable MRR, higher LTV, and cash-flow visibility; pay-per-visit lowers first-purchase friction but retains poorly.
• The commonly cited 3:1 LTV:CAC benchmark is easier to hit with subscription, because recurring refills extend lifetime value against a single acquisition cost.
• Hybrids win most often: a low or zero visit fee to enter, subscription refills to compound.
• Subscriptions carry negative-option compliance duties under FTC rules — clear disclosure, express consent, easy cancellation — and every refill still needs a valid prescription and provider review.
• Whichever model you pick, owning the patient record and refill data as the system of record is what actually compounds lifetime value.

---

neolife keeps you as the system of record for your patients, orders, and provider approvals, so recurring refills are operationally reliable enough to build a subscription business on — without replacing the storefront or pharmacy you already run. If you want the rail that makes whichever revenue model you choose actually compound, talk to us. This post is educational and not legal, medical, or financial advice; consult qualified counsel before setting pricing or subscription terms.